Download MendeleyDiscovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase.
Greco, M.N., Hawkins, M.J., Powell, E.T., Almond, H.R., de Garavilla, L., Hall, J., Minor, L.K., Wang, Y., Corcoran, T.W., Di Cera, E., Cantwell, A.M., Savvides, S.N., Damiano, B.P., Maryanoff, B.E.(2007) J Med Chem 50: 1727-1730
- PubMed: 17361995
- DOI: https://doi.org/10.1021/jm0700619
- Primary Citation of Related Structures:
2HVX - PubMed Abstract:
A series of beta-carboxamido-phosphon(in)ic acids (2) was identified as a new structural motif for obtaining potent inhibitors of human mast cell chymase. For example, 1-naphthyl derivative 5f had an IC50 value of 29 nM and (E)-styryl derivative 6g had an IC50 value of 3.5 nM. An X-ray structure for 5f.chymase revealed key interactions within the enzyme active site. Compound 5f was selective for inhibiting chymase versus eight serine proteases. Compound 6h was orally bioavailable in rats (F=39%), and orally efficacious in a hamster model of inflammation.
Organizational Affiliation:
Research and Early Development, Johnson & Johnson Pharmaceutical Research and Development, Spring House, Pennsylvania 19477-0776, USA. mgreco@prdus.jnj.com
